{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"39.445","value":"-63.74"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Cycle 3, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"35.602","value":"-71.12"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"title":"Cycle 7, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"49.885","value":"-73.10"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"69"}],"units":"Participants"}],"title":"Cycle 11, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"32.377","value":"-81.33"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"61"}],"units":"Participants"}],"title":"Cycle 17, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.283","value":"-80.84"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"}],"units":"Participants"}],"title":"Cycle 23, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.181","value":"-78.90"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"title":"Cycle 29, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"28.316","value":"-83.53"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"34"}],"units":"Participants"}],"title":"Cycle 35, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.374","value":"-83.32"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"title":"Cycle 41, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.656","value":"-81.38"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"title":"Cycle 47, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"29.094","value":"-75.83"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"16"}],"units":"Participants"}],"title":"Cycle 53, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"21.921","value":"-79.55"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"10"}],"units":"Participants"}],"title":"Cycle 59, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"26.781","value":"-68.03"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"title":"Cycle 65, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"84"}],"units":"Participants"}],"description":"Bone marrow biopsies and aspirates and peripheral blood smears were obtained for systemic mastocytosis response assessment according to mIWG-MRT-ECNM criteria. Each cycle is 28 days long.","dispersionType":"Standard Deviation","groups":[{"description":"Avapritinib was administered once daily as an immediate-release tablet, orally, in 28-day cycles.","id":"OG000","title":"Avapritinib"}],"paramType":"MEAN","populationDescription":"Safety Population: all participants who received ≥1 dose of avapritinib. Here, 'Number Analyzed' signifies those participants evaluable for this outcome measure at the specified timepoint.","reportingStatus":"POSTED","timeFrame":"Baseline up to Month 65","title":"Percent Change From Baseline in Bone Marrow Mast Cells","type":"SECONDARY","unitOfMeasure":"Percent Change"}